Evidence map›Paper›PMID 38166692›Full record

ArticleBMC neurology2024

Leukocyte differential gene expression prognostic value for high versus low seizure frequency in temporal lobe epilepsy.

Ryan Sprissler, Michael Hammer, David Labiner, Neil Joshi, Albert Alan, Martin Weinand

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ryan SprisslerCenter for Applied Genetics and Genomic Medicine, RII, University of Arizona, Tucson, AZ, USA. ryans1@email.arizona.edu.ORCID http://orcid.org/0000-0001-9250-2320
Michael HammerDepartment of Neurology, University of Arizona College of Medicine, Tucson, AZ, USA.
David LabinerDepartment of Neurology, University of Arizona College of Medicine, Tucson, AZ, USA.
Neil JoshiDepartment of Neurosurgery, University of Arizona College of Medicine, Tucson, AZ, USA.
Albert AlanDepartment of Neurosurgery, University of Arizona College of Medicine, Tucson, AZ, USA.
Martin WeinandDepartment of Neurosurgery, University of Arizona College of Medicine, Tucson, AZ, USA.
University of Arizona · US

Funding

BBB Tight Junctions During HIV-1 dementiaR01MH065151 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PERSIDSKY, YURI · 2002 to 2016
$5.9M
NIH HHS RO1MH065151NIMH NIH HHS R01 MH065151
6 · The paper itself

Abstract

backgroundThis study was performed to test the hypothesis that systemic leukocyte gene expression has prognostic value differentiating low from high seizure frequency refractory temporal lobe epilepsy (TLE).

methodsA consecutive series of patients with refractory temporal lobe epilepsy was studied. Based on a median baseline seizure frequency of 2.0 seizures per month, low versus high seizure frequency was defined as ≤ 2 seizures/month and > 2 seizures/month, respectively. Systemic leukocyte gene expression was analyzed for prognostic value for TLE seizure frequency. All differentially expressed genes were analyzed, with Ingenuity® Pathway Analysis (IPA®) and Reactome, to identify leukocyte gene expression and biological pathways with prognostic value for seizure frequency.

resultsThere were ten males and six females with a mean age of 39.4 years (range: 16 to 62 years, standard error of mean: 3.6 years). There were five patients in the high and eleven patients in the low seizure frequency cohorts, respectively. Based on a threshold of twofold change (p < 0.001, FC > 2.0, FDR < 0.05) and expression within at least two pathways from both Reactome and Ingenuity® Pathway Analysis (IPA®), 13 differentially expressed leukocyte genes were identified which were all over-expressed in the low when compared to the high seizure frequency groups, including NCF2, HMOX1, RHOB, FCGR2A, PRKCD, RAC2, TLR1, CHP1, TNFRSF1A, IFNGR1, LYN, MYD88, and CASP1. Similar analysis identified four differentially expressed genes which were all over-expressed in the high when compared to the low seizure frequency groups, including AK1, F2R, GNB5, and TYMS.

conclusionsLow and high seizure frequency TLE are predicted by the respective upregulation and downregulation of specific leukocyte genes involved in canonical pathways of neuroinflammation, oxidative stress and lipid peroxidation, GABA (γ-aminobutyric acid) inhibition, and AMPA and NMDA receptor signaling. Furthermore, high seizure frequency-TLE is distinguished prognostically from low seizure frequency-TLE by differentially increased specific leukocyte gene expression involved in GABA inhibition and NMDA receptor signaling. High and low seizure frequency patients appear to represent two mechanistically different forms of temporal lobe epilepsy based on leukocyte gene expression.

Indexed as

Epilepsy, Temporal LobeAdultFemalegamma-Aminobutyric AcidGene ExpressionHumansLeukocytesMalePrognosisReceptors, N-Methyl-D-AspartateSeizuresgamma-Aminobutyric AcidReceptors, N-Methyl-D-AspartateGene expressionLeukocyteSeizure frequencyTemporal lobe epilepsy

Identifiers

PMID38166692
PMCPMC10759702
OpenAlexW4390496459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.